RDY logo

DR. REDDY'S LABORATORIES-ADR

RDYNYSE
Earnings Jan 19US Equity
$14.11โ–ผ $0.05 (โˆ’0.35%)
Market closed ยท at close
๐Ÿ””
Track RDY
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 0.3%
7dโ–ฒ 7.0%
14dโ–ฒ 8.0%
30dโ–ฒ 11.8%
ytdโ–ฒ 0.5%
1yโ–ฒ 5.0%
๐ŸฆMarket Cap
$11.75B
Mid Cap
๐Ÿ“ˆRevenue Growth (YoY)
-3.5%
Declining
๐Ÿ“ŠGross Margin
61.1%
High
๐Ÿ’ตFCF Margin
5.5%
Moderate
โš–๏ธP/S Ratio
3.4x
Fair
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$14.10 โ€“ $14.33
52-Week Range
โ€”
Volume (shares)
165,712
Avg Volume (shares)
โ€”
Shares Outstanding
833.1M
Next Earnings
2027-01-19

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
39.8
P/S Ratio
3.4x
EPS (TTM)
โ€”
Dividend Yield
0.60%
RDY logo

DR. REDDY'S LABORATORIES-ADR

RDY
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About DR. REDDY'S LABORATORIES-ADR

Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100

Analyst Ratings

โ“˜
Consensus
Hold
42 analysts
Strong Buy8
Buy11
Hold10
Sell11
Strong Sell2
Ratings as of Oct 2026

Latest News & Updates

News unavailable.